ArticleCureus2025
COVID-19-Associated Myocarditis Managed With High-Dose Steroids: A Case of Rapid Clinical and Biochemical Recovery.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocarditis is an uncommon but serious complication of SARS-CoV-2 infection. Its diagnosis remains challenging due to clinical features overlapping with acute coronary syndromes and the lack of standardized criteria; yet, early recognition is crucial to prevent fulminant progression. We report a case of a 74-year-old woman with a recent COVID-19 infection presenting with chest discomfort, new-onset atrial fibrillation, and rising troponin levels. Despite initial treatment for non-ST elevation myocardial infarction, she experienced worsening respiratory symptoms and chest pain. Workup, including echocardiography and left heart catheterization, excluded obstructive coronary disease and revealed inferior wall hypokinesis with preserved ejection fraction. Elevated inflammatory markers (C-reactive protein (CRP), interleukin-6 (IL-6)) and clinical deterioration supported the diagnosis of COVID-19-associated myocarditis. Initiation of high-dose intravenous methylprednisolone (500 mg daily for 3 days) resulted in rapid clinical and biochemical improvement. She was discharged on a tapering dose of steroids. Six weeks of follow-up showed resolution of myocarditis with normal troponin. While evidence for steroid use in viral myocarditis is mixed, emerging case reports and reviews support immunosuppressive therapy in COVID-19-associated myocarditis. This case highlights the therapeutic benefit of high-dose corticosteroids, likely by mitigating cytokine-mediated myocardial injury. COVID-19-associated myocarditis should be considered in patients with unexplained cardiac injury and recent SARS-CoV-2 infection. Our case demonstrates that the timely administration of high-dose corticosteroids may lead to favorable outcomes. Further research is warranted to establish standardized treatment protocols and validate the efficacy of immunosuppressive therapy in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.